Artemis Announces Collaboration Agreement with Bristol-Myers
News Mar 01, 2006
Under the agreement Artemis will generate various genetically-engineered murine models carrying selected genetic mutations.
Bristol-Myers Squibb will use these models in its drug discovery research activities for the validation of drug screening targets.
Such targets are used to identify compounds and therapies for the treatment of diseases for various indications in humans.
The generation of the in vivo rodent models will be based on Artemis' proprietary ArteMice™ and ArteMice™ Conditional™ technologies.
These technologies are designed to enable the introduction of genetic sequences containing the CreER gene switch for conditional gene knock out and the creation of humanized conditional mutants in which murine genes are replaced by their human orthologues.
Quality control and transfer will be done together with Artemis' strategic partner company Taconic, which also provides use licenses to Bristol-Myers Squibb covering the U.S. territory for mouse models generated by Artemis, using techniques included in the PNS and Isogenic DNA patents.
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.